Two decades ago, WHO declared tuberculosis a global emergency, and invested in the
highly cost-effective directly observed treatment short-course programme to control the …

Existing therapies for multi-drug resistant tuberculosis (MDR-TB) have substantial
limitations, in terms of their effectiveness, side-effect profile, and complexity of …

A meta-analysis for response to treatment was undertaken using individual data of multidrug-
resistant tuberculosis (MDR-TB)(resistance to isoniazid and rifampicin) patients from 26 …

Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are associated with
worse treatment outcomes for patients, including higher mortality, than for drug-sensitive …

Multidrug-resistant (MDR) Mycobacterium tuberculosis complex (MTBC) strains represent a
major threat for tuberculosis (TB) control. Treatment of MDR-TB patients is long and less …

United Kingdom (UK) guidelines recommend at least 18 months treatment for patients with
multidrug-resistant tuberculosis (MDR-TB). Prior to 2008, data on treatment outcome were …

It is often necessary to include WHO group 5 drugs in the treatment of extensively drug-
resistant tuberculosis (XDR-TB) and fluoroquinolone-resistant multidrug-resistant …

Rationale: Levofloxacin (LFX) and moxifloxacin (MXF) are the two most frequently
recommended fluoroquinolones for treatment of patients with multidrug-resistant …

The HIV-associated tuberculosis (TB) epidemic remains a huge challenge to public health in
resource-limited settings. Reducing the nearly 0.5 million deaths that result each year has …

Fewer than 20% of patients with multidrug-resistant (MDR) tuberculosis are receiving
treatment and there is an urgent need to scale up treatment programmes. One of the biggest …